A PATH TO CONTROL FOR DIFFERENT
PATIENT TYPES

Different patients.
One DUPIXENT.

Is a patient appropriate for DUPIXENT? Build a patient based on key clinical characteristics to find out.


Patients enrolled had elevations in multiple biomarkers, including eosinophils, IgE, and FeNO1

Examples of patients with an eosinophilic phenotype or with OCS-dependent asthma

Allergic Asthma Patient with Elevated Eosinophils
She is fearful that an asthma attack will prevent her from seeing friends and family
  • EOS 155 cells/µL
  • IgE 380 IU/mL

2 severe exacerbations in the past year

Compromised lung function:
70% FEV1 % predicted

Diagnosed with asthma as a child

Positive skin test to a perennial aeroallergen

Triple therapy: ICS/LABA + LTRA

EXPLORE EXACERBATION DATA
Shortness of breath has caused him anxiety that he may miss out on quality time with his young son
  • EOS 320 cells/µL
  • IgE 430 IU/mL
  • FeNO 40 ppb

2 severe exacerbations in the past year

Compromised lung function:
65% FEV1 % predicted

Diagnosed with adult-onset asthma at age 28

Lack of asthma control

Triple therapy: High-dose ICS/LABA + LAMA

EXPLORE LUNG FUNCTION DATA

Biomarker testing not required for this patient type

The burden of sudden weight gain has left her feeling discouraged

2 severe exacerbations in the past year

Compromised lung function:
58% FEV1 % predicted

Diagnosed with adult-onset asthma at age 23

Lack of asthma control

Multiple courses of OCS treatment over 6 months, potentially leading to5:

  • Symptoms of anxiety and depression
  • Weight gain
  • Type 2 diabetes
  • Vision problems

Triple therapy: High-dose ICS/LABA + LTRA

EXPLORE OCS-DEPENDENT DATA

Patient profiles are representative and are not actual DUPIXENT patients.

99.9%
OF INSURANCE PLANS REQUIRE NO BIOMARKER TESTING FOR OCS-DEPENDENT ASTHMA PATIENTS ON DUPIXENT6

LABA, long-acting beta agonist; LAMA, long-acting muscarinic antagonist; LTRA, leukotriene receptor antagonist.

Use this guide when you
speak with your patients
about DUPIXENT

DOWNLOAD THE GUIDE

References:

  1. DUPIXENT Prescribing Information.
  2. Wenzel S, Castro M, Corren J, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet. 2016;388(10039):31-44.
  3. Data on file, Sanofi US. QUEST CSR, 2017.
  4. Rabe KF, Nair P, Brusselle G, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018;378(26):2475-2485.
  5. Price DB, Trudo F, Voorham J, et al. Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study. J Asthma Allergy. 2018;11:193-204.
  6. UnitedHealthcare. UnitedHealthcare Pharmacy Clinical Pharmacy Programs. 2019.